4.4 Article

Tyrosine hydroxylase deficiency with severe clinical course

期刊

MOLECULAR GENETICS AND METABOLISM
卷 97, 期 1, 页码 18-20

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymgme.2009.02.001

关键词

Tyrosine hydroxylase deficiency; Infantile encephalopathy; Dopa-non-responsive dystonia

向作者/读者索取更多资源

Tyrosine hydroxylase (TH) deficiency is a rare autosomal recessive disorder mapped to chromosome 11p15.5. Its clinical expression varies with presentations as dopa-responsive dystonia (recessive Segawa's disease), dopa-responsive infantile parkinsonism, dopa-responsive spastic paraplegia, progressive infantile encephalopathy or dopa-non-responsive dystonia. We describe a 7-year-old boy with progressive infantile encephalopathy and non-responsiveness to dopamine. The patient demonstrated generalized hypotonia, pyramidal tract dysfunction and temperature instability after the second month of life. Dystonia, tremor and oculogyric crises complicated the clinical picture during the following months. Neurotransmitter analysis in CSF disclosed almost undetectable levels of HVA and MHPG, whereas serum prolactin was profoundly increased. Subsequent molecular analysis revealed homozygosity for a missense mutation (c.707T > C) in the TH gene. L-Dopa therapy in both high and low doses resulted in massive hyperkinesias, while substitution with selegiline exerted only a mild beneficial effect. Today, at the age of 7 years, the patient demonstrates severe developmental retardation with marked trunkal hypotonia, hypokinesia and occasionally dystonic and/or hyperkinetic crises. He is the third Greek patient with TH deficiency to be reported. Since all three patients carry the same pathogenetic mutation, a founder effect is suspected. (C) 2009 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion

Patrick Oeckl, Sarah Anderl-Straub, Christine A. F. Von Arnim, Ines Baldeiras, Janine Diehl-Schmid, Timo Grimmer, Steffen Halbgebauer, Anna M. Kort, Marisa Lima, Taina M. Marques, Marion Ortner, Isabel Santana, Petra Steinacker, Marcel M. Verbeek, Alexander E. Volk, Albert C. Ludolph, Markus Otto

Summary: This study reveals differences in serum levels of GFAP in AD and bvFTD, showing an early increase in MCI-AD and superior diagnostic performance for AD compared to NfL.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Article Clinical Neurology

Elevated expression of urokinase plasminogen activator in rodent models and patients with cerebral amyloid angiopathy

Marc Vervuurt, Xiaoyue Zhu, Joseph Schrader, Anna M. Kort, Taina M. Marques, Iris Kersten, Annemieke M. Peters van Ton, Wilson F. Abdo, Floris H. B. M. Schreuder, Ingeborg Rasing, Gisela M. Terwindt, Marieke J. H. Wermer, Steven M. Greenberg, Catharina J. M. Klijn, H. Bea Kuiperij, William E. Van Nostrand, Marcel M. Verbeek

Summary: The aim of this study was to investigate the relationship between urokinase plasminogen activator (uPA) and cerebral amyloid angiopathy (CAA). The results showed that increased cerebrovascular expression of uPA in CAA is associated with elevated levels of uPA in cerebrospinal fluid (CSF), suggesting that uPA could serve as a biomarker for CAA.

NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2022)

Editorial Material Neurosciences

Inhibition of Neuroinflammation May Mediate the Disease-Modifying Effects of Exercise: Implications for Parkinson's Disease

Sirwan K. L. Darweesh, Nienke M. De Vries, Rick C. Helmich, Marcel M. Verbeek, Michael A. Schwarzschild, Bastiaan R. Bloem

JOURNAL OF PARKINSONS DISEASE (2022)

Review Neurosciences

Mechanisms of peripheral levodopa resistance in Parkinson's disease

Milan Beckers, Bastiaan R. Bloem, Marcel M. Verbeek

Summary: Parkinson's disease is a common neurodegenerative condition that has a significant negative impact on quality of life. Pharmacotherapy with levodopa is the main treatment, but some patients may become non-responsive to the medication, possibly due to impaired bowel motility and enzymatic abnormalities.

NPJ PARKINSONS DISEASE (2022)

Article Neurosciences

Factors associated with mortality in early stages of parkinsonism

Anouke van Rumund, Rianne A. J. Esselink, Marjolein B. Berrevoets-Aerts, Markus Otto, Bastiaan R. Bloem, Marcel M. Verbeek

Summary: Prognosis of patients with parkinsonism varies greatly between different syndromes and it is difficult to distinguish the different forms, especially in early stages. This study identified predictors of mortality and functional outcome in patients with recent-onset parkinsonism and established a simple prediction model. The model showed excellent performance in predicting functional outcome and mortality, and the findings were confirmed in an external validation cohort.

NPJ PARKINSONS DISEASE (2022)

Article Endocrinology & Metabolism

Novel cerebrospinal fluid biomarkers of glucose transporter type 1 deficiency syndrome: Implications beyond the brain's energy deficit

Tessa M. A. Peters, Jona Merx, Pieter C. Kooijman, Marek Noga, Siebolt de Boer, Loes A. van Gemert, Guido Salden, Udo F. H. Engelke, Dirk J. Lefeber, Rianne E. van Outersterp, Giel Berden, Thomas J. Boltje, Rafael Artuch, Leticia Pias-Peleteiro, Angeles Garcia-Cazorla, Ivo Baric, Beat Thoeny, Jos Oomens, Jonathan Martens, Ron A. Wevers, Marcel M. Verbeek, Karlien L. M. Coene, Michel A. A. P. Willemsen

Summary: Using next-generation metabolic screening, we identified new biomarkers for improved diagnosis and pathophysiological understanding of glucose transporter type 1 deficiency syndrome (GLUT1DS).

JOURNAL OF INHERITED METABOLIC DISEASE (2023)

Article Clinical Neurology

Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy

Anna M. De Kort, H. Bea Kuiperij, Taina M. Marques, Lieke Jakel, Emma van den Berg, Iris Kersten, Hugo E. P. van Berckel-Smit, Marco Duering, Erik Stoops, Wilson F. Abdo, Ingeborg Rasing, Sabine Voigt, Emma A. Koemans, Kanishk Kaushik, Andrew Davock Warren, Steven M. Greenberg, Gunnar Brinkmalm, Gisela M. Terwindt, Marieke J. H. Wermer, Floris H. B. M. Schreuder, Catharina J. M. Klijn, Marcel M. Verbeek

Summary: The composition of cerebrospinal fluid (CSF) may serve as a diagnostic biomarker of cerebral amyloid angiopathy (CAA), and a combined biomarker panel of CSF A beta 38, A beta 40, A beta 42, and A beta 43 has the potential to differentiate between different types of CAA and controls.

ANNALS OF NEUROLOGY (2023)

Article Biochemistry & Molecular Biology

Glycoproteomics in Cerebrospinal Fluid Reveals Brain-Specific Glycosylation Changes

Melissa Baerenfaenger, Merel A. Post, Pieter Langerhorst, Karin Huijben, Fokje Zijlstra, Joannes F. M. Jacobs, Marcel M. Verbeek, Hans J. C. T. Wessels, Dirk J. Lefeber

Summary: The glycosylation of proteins plays an important role in neurological development and disease. Glycoproteomic studies on CSF provide valuable insights into brain glycosylation. However, it is important to consider that CSF proteins mainly originate from the blood, not reflecting brain glycosylation.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Letter Clinical Neurology

Reply to Decreased Cerebrospinal Fluid Amyloid Beta 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy

Anna M. de Kort, H. Bea Kuiperij, Floris H. B. M. Schreuder, Catharina J. M. Klijn, Marcel M. Verbeek

ANNALS OF NEUROLOGY (2023)

Article Neurosciences

Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease

Emma van den Berg, Johanna Nilsson, Iris Kersten, Gunnar Brinkmalm, Anna M. de Kort, Catharina J. M. Klijn, Floris H. B. M. Schreuder, Lieke Jakel, Johan Gobom, Erik Portelius, Henrik Zetterberg, Ann Brinkmalm, Kaj Blennow, H. Bea Kuiperij, Marcel M. Verbeek

Summary: This study investigated synaptic dysfunction in cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD). The results showed that synaptic protein levels were largely unchanged in CAA patients, while they were significantly increased in AD patients. It was also found that abnormal synaptic protein levels were associated with concomitant AD pathology in CAA patients. These findings suggest a differential involvement of synaptic dysfunction in CAA and AD, possibly reflecting distinct pathological mechanisms.

JOURNAL OF ALZHEIMERS DISEASE (2023)

Article Clinical Neurology

Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy

Anna M. de Kort, H. Bea Kuiperij, Lieke Jakel, Iris Kersten, Ingeborg Rasing, Ellis S. van Etten, Sanneke van Rooden, Matthias J. P. van Osch, Marieke J. H. Wermer, Gisela M. Terwindt, Floris H. B. M. Schreuder, Catharina J. M. Klijn, Marcel M. Verbeek

Summary: Plasma A beta 42 levels may be used as a biomarker for patients with symptomatic D-CAA, while plasma A beta 38, A beta 40, and A beta 42 levels do not appear to be applicable as a biomarker in patients with sCAA.

ALZHEIMERS RESEARCH & THERAPY (2023)

Article Clinical Neurology

The association of serum vitamin D concentrations in paediatric migraine

Evangelia Ioannidou, Charalampos Tsakiris, Dimitrios G. Goulis, Athanasios Christoforidis, Dimitrios Zafeiriou

Summary: There is a significant association between serum vitamin D levels and pediatric migraine, affecting the frequency and duration of the episodes.

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2023)

Article Biochemistry & Molecular Biology

PPA1 Deficiency Causes a Deranged Galactose Metabolism Recognizable in Neonatal Screening

Melanie T. Achleitner, Judith J. M. Jans, Laura Ebner, Johannes Spenger, Vassiliki Konstantopoulou, Rene G. Feichtinger, Karin Brugger, Doris Mayr, Ron A. Wevers, Christian Thiel, Saskia B. Wortmann, Johannes A. Mayr

Summary: Two siblings showed increased levels of galactose and related metabolites in neonatal screening, but diagnostic tests did not identify abnormalities in known disease-causing enzymes. Whole-exome sequencing revealed a homozygous missense variant in the PPA1 gene, which was found to reduce enzyme activity and protein stability. The observed metabolic derangement is hypothesized to be a mild manifestation of PPA1 deficiency.

METABOLITES (2023)

Correction Biochemistry & Molecular Biology

A framework for evaluating long-term impact of newborn screening ( oct , 2023 , 10.1038/s41431-023-01469-8)

Shona Kalkman, Ron A. Wevers, Frits A. Wijburg, Mariska M. G. Leeflang

EUROPEAN JOURNAL OF HUMAN GENETICS (2023)

Meeting Abstract Clinical Neurology

AURORA: DUTCH-TYPE HEREDITARY CEREBRAL AMYLOID ANGIOPATHY NATURAL HISTORY STUDY

R. Van Dort, I. Rasing, E. Koemans, S. Voigt, K. Kaushik, R. Van der Zwet, M. Schipper, T. Van Harten, E. Van Etten, M. Verbeek, M. Van Buchem, S. Van Rooden, J. Van der Grond, E. Van Zwet, M. Van Walderveen, M. Van Osch, G. Terwindt, M. Wermer

INTERNATIONAL JOURNAL OF STROKE (2022)

暂无数据